BOLT vs CL · rev $7.7M vs P/E 34, rev $20.38B
Bolt Biotherapeutics (BOLT) versus Colgate-Palmolive Company (CL) — a side-by-side from cached financials, not a winner call.
Bolt Biotherapeutics (BOLT) is a biotechnology company listed on US.
Colgate-Palmolive Company (CL) is a household & personal products company listed on US.
Latest reported BOLT revenue for 2024-12-31 was $7.7M. Net income was -$63.1M. Revenue was down 2.4% from 2023-12-31 to 2024-12-31. BOLT currently screens at market cap $11.3M.
Latest reported CL revenue for 2025-12-31 was $20.38B. Net income was $2.13B. Revenue was up 1.4% from 2024-12-31 to 2025-12-31. CL currently screens at market cap $70.88B and trailing P/E 34.3.
BOLT currently screens at market cap $11.3M. CL currently screens at market cap $70.88B and trailing P/E 34.3.
Not investment advice. Open the BOLT and CL stock pages for the full models.
Not investment advice.